S-1/A: Bone Biologics Files Amendment No. 2 to Form S-1 Registration Statement, Updates Exhibits

Bone Biologics Corporation files an amendment to its S-1 registration statement, primarily to include updated exhibits related to an engagement agreement with H.C. Wainwright & Co., LLC.

Summary

• Bone Biologics Corporation has filed Amendment No. 2 to its Form S-1 registration statement with the SEC.
• The amendment primarily includes the filing of Exhibits 10.18 and 10.19, which pertain to an engagement agreement and its amendment with H.C. Wainwright & Co., LLC.
• The company is updating information related to expenses of issuance and distribution, indemnification of directors and officers, and recent sales of unregistered securities.
• The filing includes an exhibit index listing various agreements and legal documents incorporated by reference.
• The company undertakes to file post-effective amendments to the registration statement as required by the Securities Act of 1933.
• The document includes details of an engagement agreement between Bone Biologics and H.C. Wainwright & Co., LLC, where Wainwright will serve as the exclusive underwriter, agent, or advisor for any offering of securities during the term of the agreement.
• The company will compensate Wainwright with a cash fee of 7.0% of the aggregate gross proceeds raised in each offering, warrants to purchase 6.0% of the aggregate number of shares of common stock placed in each offering, and an expense allowance.
• Wainwright is granted a right of first refusal for various financial transactions the company may undertake in the future.
• The term of Wainwright's exclusive engagement is 90 days, with a possible extension of another 90 days if an offering is consummated within the initial term.
• The company agrees to indemnify Wainwright and its affiliates against claims related to Wainwright's activities on the company's behalf.
• Amendment No. 1 to the Engagement Agreement clarifies that the right of first refusal granted to Wainwright continues to apply for twelve months following the consummation of each offering.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The document is a regulatory filing outlining the terms of a potential securities offering and related agreements. While the engagement of an underwriter is a positive step for capital raising, the associated fees and potential liabilities create a balanced outlook.

Positives

• The engagement of H.C. Wainwright & Co., LLC provides Bone Biologics with an exclusive underwriter, agent, or advisor for securities offerings.
• The indemnification agreement protects Wainwright from potential liabilities related to their services.
• The right of first refusal ensures Wainwright has the opportunity to participate in future financial transactions by Bone Biologics.

Negatives

• The company is obligated to pay significant fees and warrants to Wainwright, potentially diluting shareholder value.
• The right of first refusal may limit the company's flexibility in choosing financial advisors for future transactions.
• The company is responsible for indemnifying Wainwright, which could result in significant expenses if claims arise.

Risks

• The consummation of any offering is subject to market conditions and Wainwright's internal approvals.
• The company is reliant on Wainwright's performance to successfully execute offerings.
• Potential claims against Wainwright could result in significant indemnification expenses for the company.
• The company's financial performance and market conditions could impact its ability to raise capital.

Future Outlook

The company intends to offer securities to the public, with the commencement date dependent on the SEC's effective date of the registration statement.

Industry Context

The engagement of an underwriter like H.C. Wainwright is a common practice for companies seeking to raise capital through securities offerings. The terms of the agreement, including fees, warrants, and rights of first refusal, are typical in the industry.

Comparison to Industry Standards

• The fees and warrant coverage provided to H.C. Wainwright are within the typical range for similar underwriting agreements.
• The right of first refusal is a standard provision that gives the underwriter an advantage in future transactions.
• The indemnification clause is a common practice to protect the underwriter from potential liabilities.

Stakeholder Impact

• Shareholders may experience dilution if the company issues new shares or warrants.
• Employees may benefit from the company's ability to raise capital for growth and development.
• Customers and suppliers may see improved stability and investment in the company's products and services.
• Creditors may be impacted by changes in the company's capital structure.

Next Steps

• The company will await the SEC's review and approval of the registration statement.
• The company and Wainwright will determine the terms of any specific offering.
• The company will file post-effective amendments as required.

Key Dates

Keywords

securities offering, H.C. Wainwright, registration statement, Bone Biologics, engagement agreement, underwriting, capital raise, indemnification, warrants, fees